62.90
Corcept Therapeutics Inc stock is traded at $62.90, with a volume of 1.20M.
It is up +1.06% in the last 24 hours and up +7.23% over the past month.
Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic and neuropsychiatric disorders by modulating the effect of the hormone cortisol.
See More
Previous Close:
$62.24
Open:
$62.06
24h Volume:
1.20M
Relative Volume:
0.83
Market Cap:
$6.59B
Revenue:
$628.56M
Net Income/Loss:
$141.82M
P/E Ratio:
49.92
EPS:
1.26
Net Cash Flow:
$142.60M
1W Performance:
-6.72%
1M Performance:
+7.23%
6M Performance:
+28.08%
1Y Performance:
+174.07%
Corcept Therapeutics Inc Stock (CORT) Company Profile
Name
Corcept Therapeutics Inc
Sector
Industry
Phone
650.688.8803
Address
101 REDWOOD SHORES PARKWAY, REDWOOD CITY
Compare CORT with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
![]()
CORT
Corcept Therapeutics Inc
|
62.90 | 6.59B | 628.56M | 141.82M | 142.60M | 1.26 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
477.52 | 127.47B | 11.02B | -535.60M | -978.00M | -2.20 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
561.49 | 62.43B | 14.20B | 4.41B | 3.54B | 38.28 |
![]()
ARGX
Argen X Se Adr
|
595.70 | 37.03B | 2.19B | 833.04M | -1.28B | 12.71 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
232.75 | 31.06B | 2.25B | -278.16M | -42.59M | -2.17 |
![]()
ONC
Beigene Ltd Adr
|
229.22 | 26.16B | 3.81B | -644.79M | -669.77M | -6.24 |
Corcept Therapeutics Inc Stock (CORT) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Nov-06-23 | Upgrade | Truist | Hold → Buy |
Apr-11-23 | Initiated | SVB Securities | Market Perform |
Apr-04-23 | Initiated | Piper Sandler | Overweight |
Feb-15-23 | Downgrade | Jefferies | Buy → Hold |
Aug-01-22 | Downgrade | Truist | Buy → Hold |
Jul-27-22 | Upgrade | Jefferies | Hold → Buy |
Jun-27-22 | Resumed | Canaccord Genuity | Buy |
Feb-02-22 | Initiated | Canaccord Genuity | Buy |
Jan-28-22 | Initiated | Truist | Buy |
Aug-05-20 | Downgrade | Jefferies | Buy → Hold |
Sep-24-19 | Initiated | Jefferies | Buy |
Sep-06-19 | Initiated | H.C. Wainwright | Buy |
Feb-04-19 | Downgrade | B. Riley FBR | Buy → Neutral |
Aug-10-18 | Reiterated | Stifel | Hold |
May-31-18 | Downgrade | Stifel | Buy → Hold |
Mar-09-18 | Initiated | B. Riley FBR, Inc. | Buy |
Aug-31-17 | Initiated | Stifel | Buy |
Feb-02-17 | Initiated | Ladenburg Thalmann | Buy |
Apr-21-15 | Initiated | FBR Capital | Outperform |
Jan-13-14 | Downgrade | Stifel | Buy → Hold |
Aug-09-13 | Downgrade | Janney | Buy → Neutral |
Aug-09-13 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
Feb-21-12 | Reiterated | JMP Securities | Mkt Outperform |
Jan-06-10 | Upgrade | Ladenburg Thalmann | Neutral → Buy |
Jul-17-08 | Initiated | Rodman & Renshaw | Mkt Outperform |
Jun-21-07 | Upgrade | Punk, Ziegel & Co | Mkt Perform → Accumulate |
View All
Corcept Therapeutics Inc Stock (CORT) Latest News
Diabetes Care Publishes Results From Prevalence Phase Of Corcept's CATALYST Trial In People With Difficult-To-Control Type 2 Diabetes | CORT Stock News - GuruFocus
Diabetes Care Publishes Results From Prevalence Phase Of Corcept'S CATALYST Trial In People With Difficult-To-Control Type 2 Diabetes - marketscreener.com
Landmark 1,000-Patient Diabetes Study Reveals Surprising Link to Cushing's Syndrome in Treatment-Resistant Cases - Stock Titan
SoundHound AI, Domo, Plug Power, Corcept, and 8x8 Shares Are Falling, What You Need To Know - Barchart.com
$1000 Invested In Corcept Therapeutics 20 Years Ago Would Be Worth This Much Today - Benzinga
It's Still Early For Corcept: With Multiple Growth Opportunities Ahead, It's No Longer Just A One Drug Wonder - Seeking Alpha
Corcept therapeutics director Daniel Swisher sells stock for $154,484 By Investing.com - Investing.com Canada
Corcept therapeutics director Daniel Swisher sells stock for $154,484 - Investing.com
Corcept Therapeutics (NasdaqCM:CORT) Rises 36% in Last Quarter - Yahoo
Corcept Initiates Trial Of Relacorilant Plus NAB-Paclitaxel And Bevacizumab - MarketScreener
Corcept Initiates Trial of Relacorilant Plus Nab-Paclitaxel and Bevacizumab in Patients With Platinum-Resistant Ovarian Cancer - Business Wire
Breakthrough Ovarian Cancer Trial Combines Three Powerful Treatments in Phase 2 Study - Stock Titan
How Some Mid Cap Stocks Outshone The S&P 400's Dramatic Drop Last Week (Mar 31-Apr 4) - Benzinga
Corcept Therapeutics (NASDAQ:CORT) Stock Price Expected to Rise, Piper Sandler Analyst Says - Defense World
Corcept Therapeutics Stock Price, Quotes and Forecasts | NASDAQ:CORT - Benzinga
Commonwealth Equity Services LLC Has $700,000 Position in Corcept Therapeutics Incorporated (NASDAQ:CORT) - Defense World
What is HC Wainwright’s Estimate for CORT FY2026 Earnings? - Defense World
Corcept therapeutics officer sells $20.2 million in stock By Investing.com - Investing.com Australia
Piper Sandler lifts Corcept stock target to $131 post-study By Investing.com - Investing.com UK
Corcept Therapeutics’ chief development officer sells $77,639 in stock By Investing.com - Investing.com India
Corcept therapeutics CEO Joseph Belanoff sells $3.37 million in shares By Investing.com - Investing.com Canada
Corcept therapeutics CEO Joseph Belanoff sells $3.37 million in shares - Investing.com Australia
Corcept therapeutics president sells shares worth $10.1 million By Investing.com - Investing.com Canada
Corcept Therapeutics’ chief development officer sells $77,639 in stock - Investing.com
Corcept therapeutics president sells shares worth $10.1 million - Investing.com
Corcept therapeutics officer sells $20.2 million in stock - Investing.com
Corcept Therapeutics Stock (CORT) Rockets Up 100% After Groundbreaking Cancer Trial Success - markets.businessinsider.com
Does Corcept (CORT) Have the Potential to Rally 28.63% as Wall Street Analysts Expect? - Yahoo Finance
Corient Private Wealth LLC Purchases New Holdings in Corcept Therapeutics Incorporated (NASDAQ:CORT) - Defense World
Corcept Therapeutics (NASDAQ:CORT) Given New $142.00 Price Target at Canaccord Genuity Group - Defense World
Corcept's ovarian cancer drug meets main goal in late-stage study, shares jump - MSN
Corcept Therapeutics stock target raised to $150 by H.C. Wainwright - Investing.com Canada
Corcept Therapeutics (CORT) Stock Surges Following Positive Tria - GuruFocus
Corcept Therapeutics (CORT) Surges 109% Following Positive Trial Results - GuruFocus
U.S. Markets Ended Tuesday Mixed As monday.com Led, Corcept Therapeutics Lagged - Barron's
Yum Brands (YUM) Seeks New CEO as Corcept (CORT) and Hut 8 (HUT) Shares Climb - GuruFocus
Corcept Therapeutics Unusual Options Activity For April 01 - Benzinga
Daily Digest: State Farm's newest rate hike request; Stock soars on cancer results - The Business Journals
CORT Shares Rise as Relacorilant Combo Meets Ovarian Cancer Study Goal - TradingView
Corcept's relacorilant trial in patients with platinum-resistant ovarian cancer meets primary endpoint - Pharmafile
Corcept (CORT) Stock Jumps 109.1%: Will It Continue to Soar? - Nasdaq
Truist Securities lifts Corcept Therapeutics target to $150 - Investing.com
Here's Why Momentum in Corcept (CORT) Should Keep going - Yahoo Finance
Corcept Therapeutics: The ROSELLA Trial Presents A Major Win For The Company - Seeking Alpha
Why Corcept Therapeutics Incorporated (CORT) Went Up On Monday? - Yahoo
Corcept Therapeutics Reaches Analyst Target Price - Nasdaq
Corcept Therapeutics Shares Surge 109% to $114.22 on Phase 3 Trial Breakthrough - TradingPedia
Corcept’s Phase III trial of ovarian cancer therapy shows PFS improvement - Yahoo Finance
HC Wainwright Issues Positive Forecast for Corcept Therapeutics (NASDAQ:CORT) Stock Price - Defense World
AIG, Corcept Therapeutics, Dow - TradingView
Truist Financial Issues Positive Forecast for Corcept Therapeutics (NASDAQ:CORT) Stock Price - Defense World
Corcept Therapeutics Inc Stock (CORT) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):